Incyte Corporation (INCY)

Name: Incyte Corporation (INCY) — histórico de demonstrações financeiras
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.

Health Care · Wall Street (EUA) · Última atualização: 2026-09-19

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.

Números-chave

Capitalização de mercado: $25 billion
Receita (exercício encerrado em 2025-12-31): $5.1B
Lucro líquido: $1.3B
Margem bruta: 92.8%
Margem líquida: 25.0%

Ver gráficos interativos e demonstrações completas → Modelo de avaliação (DCF) →

Demonstração de resultados anual

Demonstração de resultados	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Receita total	$5.8B	$5.1B	$4.2B	$3.7B	$3.4B	$3.0B	$2.7B	$2.2B	$1.9B	$1.5B	$1.1B	$754M	$511M	$355M	$297M	$94M	$170M	$9M	$4M	$34M	$28M
Lucro bruto	$5.4B	$4.8B	$3.9B	$3.4B	$3.2B	$2.8B	$2.5B	$2.0B	$1.8B	$1.5B	$1.0B	$727M	$508M	$354M	$297M	$94M	$170M	$9M	$4M	$34M	$28M
Margem Bruta %	92.6%	92.8%	92.6%	93.1%	93.9%	94.9%	95.1%	94.7%	95.0%	94.8%	94.7%	96.4%	99.4%	99.8%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Resultado Operacional (EBIT)	$1.8B	$1.3B	$101M	$655M	$592M	$586M	($264M)	$402M	$129M	($243M)	$145M	$51M	($5M)	($16M)	$1M	($143M)	$14M	($140M)	($159M)	($85M)	($77M)
% de margem operacional	31.6%	26.1%	2.4%	17.7%	17.4%	19.6%	-9.9%	18.6%	6.9%	-15.8%	13.1%	6.7%	-0.9%	-4.5%	0.4%	-151.6%	8.3%	-1508.6%	-4064.5%	-247.6%	-278.1%
Resultado líquido	$1.6B	$1.3B	$33M	$598M	$341M	$949M	($296M)	$447M	$109M	($313M)	$104M	$7M	($48M)	($83M)	($44M)	($187M)	($32M)	($212M)	($179M)	($87M)	($74M)
Margem Líquida %	27.7%	25.0%	0.8%	16.2%	10.0%	31.8%	-11.1%	20.7%	5.8%	-20.4%	9.4%	0.9%	-9.5%	-23.4%	-14.9%	-197.5%	-18.8%	-2286.8%	-4565.4%	-252.3%	-268.3%
EBITDA	—	$1.8B	$408M	$919M	$600M	$630M	($178M)	$543M	$172M	($253M)	$205M	$98M	$40M	($15M)	$32M	($116M)	$36M	($123M)	($146M)	($72M)	($69M)
Lucro por ação (EPS)	$7.85	$6.41	$0.15	$2.65	$1.52	$4.27	$-1.36	$2.05	$0.51	$-1.53	$0.54	$0.03	$-0.29	$-0.56	$-0.34	$-1.49	$-0.26	$-2.06	$-1.99	$-1.03	$-0.89
Ações em circulação (M)	—	201M	211M	226M	224M	222M	218M	218M	216M	205M	194M	187M	168M	148M	130M	125M	122M	103M	90M	84M	84M

Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.

Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de INCY. /companies/us/INCY

Empresas semelhantes

BIIB · Biogen

As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.

English version →Todas as ações

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.